Form 4: YD Bio Director Kochi Chang Reports Share Unit Vesting

Kochi Chang, a Director at YD Bio Ltd, reported the vesting of 5,749 Restricted Share Units (RSUs) on June 30, 2026, which represent contingent rights to ordinary shares.

Summary

• Kochi Chang, a Director at YD Bio Ltd, has filed a Form 4 reporting a transaction on June 30, 2026.
• The transaction involved the vesting of 5,749 Restricted Share Units (RSUs).
• Each RSU represents a contingent right to receive one ordinary share of YD Bio Limited.
• These RSUs were granted under the YD Bio Limited Equity Incentive Plan.
• The grant date fair value was $60,000 on March 31, 2026, with vesting in four equal quarterly installments.
• The number of RSUs vesting is determined by dividing $15,000 by the seven-day volume-weighted average price of the company's ordinary shares prior to the vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction related to executive compensation rather than significant financial performance or strategic shifts.

Positives

• Vesting of share units indicates continued commitment and potential future value realization for the director.
• The equity incentive plan suggests a strategy to retain and motivate key personnel.

Negatives

• The filing does not contain information that would be considered negative in a financial reporting context.

Risks

• The value of the vested RSUs is subject to the market price of YD Bio Limited's ordinary shares, which can be volatile.
• The vesting schedule and calculation method tied to share price introduce uncertainty regarding the exact number of shares received.

Future Outlook

The vesting of RSUs is tied to the company's share price performance, implying that future value realization for the reporting person is dependent on the company's stock performance.

Industry Context

StockSavvy.ai notes that the reporting of RSU vesting is a standard disclosure for public companies under SEC regulations, reflecting common executive compensation practices in the biotechnology sector.

Stakeholder Impact

• Shareholders: The vesting of RSUs does not directly impact current share price but reflects ongoing executive compensation practices.
• Employees: The equity incentive plan may serve as a motivator for other employees if similar plans are in place.
• Management: Confirms the compensation structure for directors and potentially other key executives.

Next Steps

• The reporting person will continue to vest in RSUs according to the schedule outlined in the Equity Incentive Plan.
• Future transactions by the reporting person will be subject to SEC disclosure requirements.

Key Dates

Keywords

Form 4, SEC Filing, YD Bio Ltd, Kochi Chang, Director, Restricted Share Units, RSU Vesting, Equity Incentive Plan, Beneficial Ownership, Insider Trading